NCT02680782View on ClinicalTrials.gov

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

February 28, 2016

Study Completion Date

February 28, 2016

Conditions
Healthy
Interventions
DRUG

X4P-001

100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.

Trial Locations (1)

32117

Covance CRU, Inc., Daytona Beach

Sponsors

Lead Sponsor

X4 Pharmaceuticals

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

X4 Pharmaceuticals

INDUSTRY

NCT02680782 - A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers | Biotech Hunter | Biotech Hunter